Suppliers / Procter & Gamble Manufacturing México, S. De R.L. De C.V

Procter & Gamble Manufacturing México, S. De R.L. De C.V

Mexico Updated 9 July 2026

Procter & Gamble Manufacturing México, S. De R.L. De C.V is a finished-dose manufacturer based in Mexico. It appears in 39 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with DIGEMAPS (DO), MINSA (CR) and COFEPRIS (MX). Its GMP standing is certified by ANVISA (Brazil), COFEPRIS (MX) and US FDA. Its most recent recorded inspection, by US FDA, closed on 27 June 2025 as VAI. Customs aggregates show $94K of exports covering 11 molecules to 2 destinations in 2024.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
39
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 27 June 2025 VAI US FDA
  • 15 June 2018 VAI US FDA
  • 6 March 2015 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
NAUCALPAN DE JUAREZ, Mexico Not on file
Mexico, Mexico 3002744909
Naucalpan de Juárez, Mexico Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
DIGEMAPS (DO) 29 None
MINSA (CR) 9 None
COFEPRIS (MX) 1 2
ANVISA (Brazil) None 4
US FDA None 1

Scale

Year Revenue Exports Destinations
2024 Not reported $94K 2
2023 Not reported $31.9M 14
2022 Not reported $56.9M 14

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Procter & Gamble Manufacturing México, S. De R.L. De C.V comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 27 June 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts